Oncology Institute Inc
NASDAQ:TOI
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.1718
  • TODAY'S CHANGE (%)
    -0.0082 (-4.5556%)
  • Bid / Lots
    0.1680/ 157
  • Ask / Lots
    0.1718/ 3
  • Open / Previous Close
    0.1940 / 0.1800
  • Day Range
    0.1661
    0.1940
  • 52 Week Range
    0.1661
    2.5000
  • Volume
    924,540

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 13, 2024

      Show headlines and story abstract

    • 4:12PM ET on Wednesday Nov 13, 2024 by MT Newswires
      Companies Mentioned: TOI
      04:12 PM EST, 11/13/2024 (MT Newswires) -- ...

    • 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
      Companies Mentioned: TOI
      Unrealized (gain) loss on investments (134) (44) Accretion of discount on investment securities (499) (712) Deferred taxes -- 50 Credit losses -- 31 Loss on disposal of property and equipment 51 -- Changes in operating assets and liabilities: Accounts receivable (12,142) (8,657) Other receivables 193 153 Inventories 3,572 (2,913) Prepaid expenses and other current assets (8) 2,728 Operating right-of-use assets 2,086 4,448 Other assets (27) (83) Accounts payable 8,476 3,961 Current and long-term operating lease liabilities (1,436) (3,909) Accrued expenses and other current liabilities 4,815 579 Income taxes payable -- -- Other non-current liabilities (204) (394) ------- ------- Net cash and cash equivalents used in operating activities (30,724) (32,422) Cash flows from investing activities: Purchases of property and equipment (2,034) (3,706) Cash paid for practice acquisitions, net -- (4,300) Purchases of marketable securities/investments -- (9,683) Sales of marketable securities/investments 50,000 68,702 ------- ------- Net cash and cash equivalents provided by investing activities 47,966 51,013 Cash flows from financing activities: Payments made for financing of insurance payments (1,002) (3,010) Payment of deferred consideration liability for acquisition (2,372) (959) Principal payments on financing leases (29) (91) Common stock repurchase -- (1,019) Common stock issued for options exercised 75 13 Net cash and cash equivalents used in financing activities (3,328) (5,066) ------- ------- Net increase in cash and cash equivalents 13,914 13,525 Cash and cash equivalents at beginning of period 33,488 14,010 ------- ------- Cash and cash equivalents at end of period $ 47,402 $ 27,535 ======= =======

    • 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
      Companies Mentioned: TOI
      Unrealized (gain) loss on investments (134) (44) Accretion of discount on investment securities (499) (712) Deferred taxes -- 50 Credit losses -- 31 Loss on disposal of property and equipment 51 -- Changes in operating assets and liabilities: Accounts receivable (12,142) (8,657) Other receivables 193 153 Inventories 3,572 (2,913) Prepaid expenses and other current assets (8) 2,728 Operating right-of-use assets 2,086 4,448 Other assets (27) (83) Accounts payable 8,476 3,961 Current and long-term operating lease liabilities (1,436) (3,909) Accrued expenses and other current liabilities 4,815 579 Income taxes payable -- -- Other non-current liabilities (204) (394) ------- ------- Net cash and cash equivalents used in operating activities (30,724) (32,422) Cash flows from investing activities: Purchases of property and equipment (2,034) (3,706) Cash paid for practice acquisitions, net -- (4,300) Purchases of marketable securities/investments -- (9,683) Sales of marketable securities/investments 50,000 68,702 ------- ------- Net cash and cash equivalents provided by investing activities 47,966 51,013 Cash flows from financing activities: Payments made for financing of insurance payments (1,002) (3,010) Payment of deferred consideration liability for acquisition (2,372) (959) Principal payments on financing leases (29) (91) Common stock repurchase -- (1,019) Common stock issued for options exercised 75 13 Net cash and cash equivalents used in financing activities (3,328) (5,066) ------- ------- Net increase in cash and cash equivalents 13,914 13,525 Cash and cash equivalents at beginning of period 33,488 14,010 ------- ------- Cash and cash equivalents at end of period $ 47,402 $ 27,535 ======= =======

  • Nov 11, 2024

Peers Headlines